Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Senior Solution Marketing Manager
About the author:
As a Senior Solution Marketing Manager at Elsevier, Sherry is responsible for delivering insights on markets and customers, messaging, positioning and thought leadership for life science solutions, including PharmaPendium, that enable Drug Discovery and Development and Pharmacovigilance.
Sherry has a PhD in Medical Genetics from the University of Toronto, Canada and has several years of experience in life science marketing and communications, having worked at QIAGEN in Hilden, Germany before joining Elsevier and also in Research Communications at the University Health Network in Toronto, Canada. Prior to this, Sherry performed research at cancer institutes in both Canada and the US.
Posts by Sherry Winter
Posted on December 4th, 2017 in Pharma R&D
In a piece featured in the PharmaTimes, Katrina Megget points out the sad state of affairs when it comes to clinical trials, highlighting some appalling stats on the frequent failure to reach enrollment targets (in some cases, not finding any patients at all) and the tendency for studies to go on far longer than anticipated. Continue reading “Extreme Makeover: Clinical Trials Edition” »
Posted on October 27th, 2017 in Pharmacovigilance
In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »
Posted on September 29th, 2017 in Pharma R&D
Widespread underreporting is often cited as a factor that curtails the analytical value of data from spontaneous reporting systems. Voluntary submission of reports is a core feature of these systems but it also means that not all events suspected to be associated with a medicinal product are documented and brought to the attention of authorities and marketing authorization holders – Continue reading “Streamlining Detection Strategies for Signal Detection” »
Posted on September 25th, 2017 in Pharma R&D
In 2012, the U.S. Food and Drug Administration (FDA) provided draft guidance for the industry on drug interaction studies, stating that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.” Continue reading “Reducing Adverse Event Risk” »